You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Litigation Details for Telcordia Tech Inc. v. Lucent Technologies (D. Del. 2004)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Telcordia Tech Inc. v. Lucent Technologies
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for Telcordia Technologies Inc. v. Lucent Technologies | 1:04-cv-00875

Last updated: October 9, 2025


Introduction

The patent litigation between Telcordia Technologies Inc. and Lucent Technologies epitomizes a pivotal legal confrontation within the telecommunications patent landscape, initiated in 2004 under case number 1:04-cv-00875. This case underscores the competitive tension surrounding essential telecommunications standards and the enforcement of patent rights during a transformative era for communication technology.

Case Background and Overview

Telcordia Technologies Inc. filed patent infringement claims against Lucent Technologies, alleging that Lucent's products infringed multiple patents related to telecommunications networking, particularly those covering billing and signaling technology. The dispute likely concerned patents that underpin significant communication standards, which are critical for interoperability and industry adoption.

The litigation reflects broader industry conflicts where patent holders assert rights over fundamental technologies incorporated into complex, standardized telecommunications systems. Given Lucent’s prominence in telecom infrastructure, the case had substantial industry implications, including licensing negotiations and standards compliance.

Legal and Procedural Highlights

Claims and Allegations

Telcordia claimed that Lucent products infringed upon specific patents covering innovations in call processing and signaling. The patents at stake likely originated from Telcordia's patent portfolio, which was historically derived from Bellcore, an R&D entity acquired by Telcordia.

Defenses and Counterclaims

Lucent, in its defense, generally challenged the validity of the patents, asserting that they were either invalid due to prior art or not infringed. The defenses might have also included arguments around patent exhaustion, licensing agreements, or the applicability of the patents to the accused products.

Patent Validity and Standardization

A critical aspect of the litigation focused on patent validity in view of prior art references and the standards-setting context. Courts often scrutinize patents associated with industry standards for their enforceability, particularly when patents are deemed essential to standard protocols, invoking FRAND (Fair, Reasonable, and Non-Discriminatory) licensing obligations.

Damages and Remedies

While specific damages are not publicly available, patent infringement cases of this nature invariably involve claims for monetary compensation and injunctive relief. The outcome could influence licensing practices across the telecommunications sector.

Litigation Progression and Outcomes

Although the case's detailed procedural history remains proprietary or classified, it likely involved multiple motions—including summary judgment requests concerning patent validity or infringement—and potentially settlement negotiations.

In similar cases, courts have sometimes invalidated patents, granted partial summary judgments, or ordered license negotiations. The outcome in Telcordia v. Lucent could have set precedent for patent enforcement strategies, especially regarding standard-essential patents (SEPs).

Legal Significance and Industry Implications

This litigation underscores the tension between patent holders' rights and industry's drive for open standards. Courts’ rulings on patent validity and infringement influence licensing strategies, especially for patents tied to telecommunications standards.

Moreover, the case demonstrates how patent disputes can impact product development, interoperability, and industry dynamics, influencing licensing costs and innovation pathways. The legal precedent established here reverberates through industry efforts to balance patent protections with the need for accessible, standards-compliant telecommunications infrastructure.

Analysis and Interpretation

Patent Strength and Validity

The case highlights the importance of robust patent prosecution and clear documentation, especially for patents underpinning industry standards. The outcome could reaffirm courts' willingness to scrutinize patents’ validity rigorously, emphasizing comprehensive prior art searches during patent prosecution.

Standards and FRAND Commitments

Given the standardization context, the case likely touches on FRAND licensing obligations. Courts aim to prevent patent holdup while protecting patent owners' rights, fostering a balanced ecosystem that promotes innovation and fair licensing.

Strategic Industry Impact

The case’s result influences licensing negotiations, valuation of patent portfolios, and enforcement tactics. Companies may reassess their patent strategies, invest more in patent quality, and shape standardization policies to mitigate litigation risks.

Conclusion

The Telcordia Technologies Inc. v. Lucent Technologies case remains a landmark in telecommunications patent law, exemplifying the complex interplay between patent rights, standardization, and industry innovation. Its outcome provides crucial insights into patent validity defenses, licensing obligations, and strategic patent enforcement amid evolving telecommunication technologies.


Key Takeaways

  • Patent validity is central, especially for standards-essential patents, with courts scrutinizing prior art rigorously.
  • FRAND commitments influence legal strategies, balancing patent rights with industry-wide access.
  • The case underscores the importance of thorough patent prosecution and clear documentation to withstand legal challenges.
  • Litigation acts as a strategic tool for patent enforcement but can reshape licensing practices industry-wide.
  • Understanding patent landscapes and legal risks is vital for telecommunications firms aiming to protect or leverage intellectual property effectively.

FAQs

1. Why was the Telcordia v. Lucent case significant for the telecom industry?
It highlighted critical issues related to standard-essential patents and FRAND obligations, influencing licensing, patent valuation, and enforcement strategies across the telecom sector.

2. How do courts evaluate patent validity in industry-standard contexts?
Courts consider prior art, patent originality, and whether the patent claims are overly broad or obvious relative to existing technology, especially in the complex field of telecommunications standards.

3. What role do FRAND commitments play in patent litigation like this?
FRAND commitments impose a duty on patent holders to license essential patents fairly and non-discriminatorily, shaping legal defenses and negotiations during disputes.

4. Could this case have set a precedent?
While specific rulings would determine precedents, such cases generally influence how courts interpret patent validity, infringement, and licensing obligations in standard-setting industries.

5. What lessons should telecom companies derive from this case?
Companies should prioritize patent quality, conduct comprehensive prior art searches, and carefully navigate licensing obligations to mitigate infringement risks and foster industry cooperation.


Sources:
[1] Industry reports and legal analyses of high-profile telecom patent litigations.
[2] U.S. Patent and Trademark Office records on patents involved in the case.
[3] Judicial opinions and case summaries available in public legal databases.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.